Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Jingjing Wu; Mingzhi Zhang; Delong Liu

doi:10.18632/oncotarget.12786

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Jingjing Wu, Mingzhi Zhang and Delong Liu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:7201-7207. https://doi.org/10.18632/oncotarget.12786

Metrics: PDF 3003 views | HTML 4397 views | ?

Abstract

Jingjing Wu1, Mingzhi Zhang1 and Delong Liu1

1 Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Correspondence to:

Delong Liu, email:

Keywords: Bruton tyrosine kinase, ONO/GS-4059, ibrutinib

Received: September 20, 2016 Accepted: October 10, 2016 Published: October 20, 2016

Abstract

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLCγ2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12786

Publication Alerts

Reviews:

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Abstract